10,240 Shares of Edwards Lifesciences Corporation $EW Bought by NTV Asset Management LLC

NTV Asset Management LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, Holdings Channel.com reports. The firm purchased 10,240 shares of the medical research company’s stock, valued at approximately $884,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 1.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock valued at $627,000 after buying an additional 132 shares during the last quarter. NorthRock Partners LLC grew its stake in shares of Edwards Lifesciences by 1.0% in the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock valued at $1,465,000 after buying an additional 153 shares in the last quarter. Elevation Wealth Partners LLC increased its holdings in Edwards Lifesciences by 24.8% in the third quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company’s stock worth $67,000 after buying an additional 155 shares during the last quarter. Plan A Wealth LLC increased its holdings in Edwards Lifesciences by 3.0% in the third quarter. Plan A Wealth LLC now owns 5,460 shares of the medical research company’s stock worth $471,000 after buying an additional 158 shares during the last quarter. Finally, Premier Path Wealth Partners LLC increased its holdings in Edwards Lifesciences by 4.4% in the first quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company’s stock worth $311,000 after buying an additional 162 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 5,045 shares of company stock valued at $451,596. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Sanford C. Bernstein lifted their target price on shares of Edwards Lifesciences from $96.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Evercore reissued an “outperform” rating on shares of Edwards Lifesciences in a research report on Friday. Rothschild & Co Redburn increased their price target on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Finally, Raymond James Financial increased their price target on shares of Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $89.15 on Monday. The stock has a market capitalization of $51.33 billion, a P/E ratio of 51.23, a P/E/G ratio of 2.33 and a beta of 0.87. The business has a 50-day moving average of $88.05 and a two-hundred day moving average of $86.65. Edwards Lifesciences Corporation has a fifty-two week low of $74.66 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 3.00 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.